The double-edged peptide: how a metabolic hormone can turn toxic

Health · Published 18 October 2026 Swipe more like this →

In short: Amylin is a master regulator of your metabolism, working alongside insulin to manage blood sugar and satiety. But in the body of a diabetic, this essential peptide can undergo a structural transformation, aggregating into toxic fibrils that may contribute to both metabolic and neurological decay.

Primarily released from pancreatic beta cells, the 37-residue peptide hormone amylin is frequently identified as islet amyloid polypeptide (IAPP). It is co-secreted with insulin in a ratio of approximately 100:1. Its primary physiological roles include regulating food intake, slowing gastric emptying, and promoting satiety. These functions help prevent rapid spikes in blood glucose levels following a meal. Minor amounts of amylin are generated by spinal ganglia, the gastrointestinal tract, and neurons, in addition to the pancreas.

The production of amylin is closely linked to insulin. Both are regulated by similar factors and share a common regulatory promoter motif. Because they are co-secreted, conditions that increase insulin production—such as insulin resistance in Type 2 diabetes—can lead to a corresponding increase in proIAPP production. However, as the disease progresses, impaired beta-cell function due to glucotoxicity or lipotoxicity can cause a parallel reduction in the release of both insulin and amylin, a trend also associated with human aging.

The pathology of amylin lies in its tendency to aggregate. In patients with Type 2 diabetes, IAPP can form toxic amyloid fibrils and beta-sheets, leading to amyloid plaques in the pancreas, brain, and blood vessels. These deposits are linked to the progression of diabetes and have been observed in patients with cognitive deficits. Research suggests that while amylin is vital for metabolic balance, its transition into these pathological aggregates may contribute to neurodegeneration, including Alzheimer's disease, and various cerebrovascular disorders.

Current research is exploring amylin as a dual-purpose therapeutic target. Scientists are investigating how to maintain its metabolic benefits—such as slowing gastric emptying and reducing meal size—while preventing its transition into toxic deposits. For instance, certain human antibodies have shown potential in protecting beta cells from these aggregates in Type 2 diabetes models. Understanding this delicate balance between physiological function and pathological aggregation is key to treating complex cardiometabolic and neurological diseases.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• The molecular shadow that reveals how your body makes insulin
• The anabolic architect of your body's energy storage
• The metabolic seesaw: how two hormones balance your blood sugar
• Insulin resistance lets blood sugar look normal while the pancreas works overtime
• The gut hormone behind today's weight-loss drugs survives about two minutes
• When brain proteins turn blood vessels into fragile, leaking pipes
• The tiny, rice-sized glands controlling your body's calcium balance
• Prediabetes is a reversible early warning, not a permanent destiny
• The kidney's hidden chemical switch for blood pressure
• Why a single blood ratio might predict your hospital stay
• The hormone that balances your body's internal thermostat and memory
• Can a simple tax change the way we drink?

More in Diabetes · More in Health · Latest · A–Z · All topics